The global breast cancer liquid biopsy market is witnessing significant growth, fueled by technological advancements and rising demand for non-invasive diagnostic solutions. Valued at USD 200 million in 2024, the market expanded to USD 229.6 million in 2025 and is projected to reach approximately USD 795.42 million by 2034, registering a robust CAGR of 14.8% (2025–2034).

North America dominated with a revenue share of 44–45% in 2024, while Asia Pacific is expected to emerge as the fastest-growing region. Among circulating biomarkers, the cfDNA/ctDNA segment captured a 44–54% share in 2024.

This article highlights top companies in the breast cancer liquid biopsy market, with insights into their businesses, key products, and market positions.

---

🌐 Top Companies Driving the Breast Cancer Liquid Biopsy Market

1️⃣ F. Hoffmann-La Roche Ltd.

About: A global leader in healthcare, Roche specializes in pharmaceuticals and diagnostics.
Products: Notable for its liquid biopsy solutions like the AVENIO ctDNA Analysis Kits.
Market Cap: Approx. $220 billion (as of 2025).

---

2️⃣ QIAGEN N.V.

About: QIAGEN provides sample and assay technologies for molecular diagnostics.
Products: Offers QIAseq Targeted DNA Panels for cancer research and diagnostics.
Market Cap: Around $11 billion (2025).

---

3️⃣ Thermo Fisher Scientific, Inc.

About: A leading supplier of scientific instrumentation and reagents.
Products: Known for Oncomine™ Liquid Biopsy Assay solutions.
Market Cap: Over $220 billion (2025).

---

4️⃣ Myriad Genetics, Inc.

About: Focused on genetic testing and precision medicine.
Products: Offers myRisk® Hereditary Cancer testing and liquid biopsy services.
Market Cap: Estimated at $2 billion (2025).

---

5️⃣ Guardant Health, Inc.

About: Specializes in liquid biopsy for advanced cancer diagnostics.
Products: Guardant360® and Guardant Reveal™ for early-stage cancer detection.
Market Cap: Approximately $6 billion (2025).

---

6️⃣ NeoGenomics Laboratories

About: Provides cancer-focused testing services globally.
Products: Includes liquid biopsy assays for solid tumor profiling.
Market Cap: Around $1 billion (2025).

---

7️⃣ Biocept, Inc.

About: Pioneers in liquid biopsy technologies for cancer detection.
Products: Target Selector™ platform for breast cancer monitoring.
Market Cap: Small-cap, approx. $50 million (2025).

---

8️⃣ Fluxion Biosciences, Inc.

About: Innovator in single-cell analysis and liquid biopsy solutions.
Products: IsoFlux™ Liquid Biopsy System.
Market Cap: Privately held.

---

9️⃣ Epic Sciences, Inc.

About: Focuses on circulating tumor cell (CTC) detection technologies.
Products: Epic CTC Platform enabling real-time cancer monitoring.
Market Cap: Privately held.

---

10️⃣ Sysmex Corporation

About: Japan-based firm specializing in diagnostics and lab equipment.
Products: Liquid biopsy solutions for oncology testing.
Market Cap: Over $15 billion (2025).

---

11️⃣ Illumina, Inc.

About: Global leader in DNA sequencing and genomic analysis.
Products: NGS platforms supporting liquid biopsy applications.
Market Cap: Approx. $30 billion (2025).

---

12️⃣ Biodesix, Inc.

About: Specializes in lung cancer diagnostics and liquid biopsy tests.
Products: GeneStrat® and Nodify™ platforms.
Market Cap: Small-cap, approx. $150 million (2025).

---

13️⃣ Menarini Silicon Biosystems

About: Focused on cell-based diagnostics for oncology.
Products: DEPArray™ technology for CTC isolation.
Market Cap: Subsidiary of Menarini Group.

---

14️⃣ Johnson & Johnson (Janssen Diagnostics)

About: Part of J&J’s diagnostics division targeting cancer detection.
Products: Developing CTC-based liquid biopsy technologies.
Market Cap: Parent company J&J approx. $480 billion (2025).

---

15️⃣ Foundation Medicine (Roche)

About: Subsidiary of Roche offering comprehensive genomic profiling.
Products: FoundationOne® Liquid CDx.
Market Cap: Fully integrated into Roche.

---

16️⃣ Cynvenio Biosystems, Inc.

About: Provides personalized liquid biopsy solutions.
Products: ClearID® Breast Cancer assay.
Market Cap: Privately held.

---

17️⃣ Twist Bioscience

About: Specializes in synthetic DNA for research and diagnostics.
Products: Supports liquid biopsy applications with DNA libraries.
Market Cap: Approx. $2 billion (2025).

---

📈 Breast Cancer Liquid Biopsy Market Insights

• Market Size: USD 229.6 million in 2025; projected USD 795.42 million by 2034.

• Growth Rate: 14.8% CAGR (2025–2034).

• Regional Highlights: North America leads; Asia Pacific growing fastest.

• Biomarker Insights: cfDNA/ctDNA segment dominates (44–54% share in 2024).

Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com

---

❓ Frequently Asked Questions (FAQs)

1. What is driving the breast cancer liquid biopsy market growth?

Technological advancements, rising breast cancer incidence, and demand for non-invasive diagnostics are key drivers.

2. Which region dominates the market?

North America holds the largest share (44–45%), followed by Europe.

3. Which biomarker segment is leading in 2024?

The cfDNA/ctDNA segment holds the largest share at 44–54%.

4. Who are the top players in this market?

Companies like Roche, QIAGEN, Thermo Fisher, and Guardant Health are leading the market.

5. What is the forecasted market size by 2034?

The market is projected to reach approximately USD 795.42 million by 2034.

Source : https://www.towardshealthcare.com/insights/breast-cancer-liquid-biopsy-market-sizing

Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5883